Montelukast: A review of its therapeutic potential in asthma in children 2 to 14 years of age

Pediatric Drugs

Volumn 4, Issue 2, 2002, Pages 123-139

  Muijsers, Richard B R ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Asthma; Children; Montelukast; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CROMOGLYCATE DISODIUM; DIGOXIN; FEXOFENADINE; MONTELUKAST; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PREDNISOLONE; PREDNISONE; TERFENADINE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ASTHMA; BRONCHOSPASM; COUGHING; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036194385     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204020-00005     Document Type: Review

References (116)

1. Global strategy for asthma management and prevention
2. The British guidelines on asthma management 1995 review and position statement
3. Expert panel report 2: Guidelines for the diagnosis and management of asthma. July 1997 update
4. Present and future treatment of asthma in infants and young children
5. The role of inflammation in childhood asthma
6. Bronchoalveolar cell profiles in children with asthma, infantile wheeze, chronic cough, or cystic fibrosis
7. Bronchoalveolar lavage findings suggest two different forms of childhood asthma
8. Montelukast: A review of its therapeutic potential in persistent asthma
9. Pharmacological inhibition of leukotriene actions
10. Pharmacological characterization of leukotriene receptors
11. 1 receptor
12. Rationale for leukotriene receptor antagonists as controller therapy for asthma
13. Antileukotriene therapy: Future directions
14. Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways
15. Leukotrienes as mediators of airway obstruction
16. Inflammation, leukotrienes and the pathogenesis of the late asthmatic response
17. Childhood asthma and allergic rhinitis: The role of leukotrienes
18. Leukotrienes, Leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: An update. Part II: Clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma
19. Leukotrienes, Leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: An update. Part I: Synthesis, receptors and role of leukotrienes in asthma
20. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma
21. Measurements of leukotrienes in the urine: Strategies and applications
22. Urinary mediators and asthma
23. Induced sputum eicosanoid concentrations in asthma
24. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions
25. Can asthma be studied in urine?
26. 4 excretion in allergic asthmatics after inhaled antigen
27. Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants: Modulation by dexamethasone
28. Treatment of asthma with drugs modifying the leukotriene pathway
29. Leukotrienes and airway responses
30. 4, and histamine in normal human subjects
31. Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi
32. Inherent tone of human bronchus: Role of eicosanoids and the epithelium
33. Leukotriene bronchoconstriction induced by allergen and exercise
34. 4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects
35. 4 and methacholine on sputum cell differentials in asthma
36. 4 receptor antagonist pranlukats, or an interleukin-5 monoclonal antibody
37. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively sensitized guinea pig
38. 4 and granulocytic infiltration into asthmatic airways
39. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
40. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma
41. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects
42. 4 receptor antagonist
43. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children
44. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma
45. Mediator involvement in antigen-induced bronchospasm and microvascular leakage in the airways of ovalbumin sensitized Brown Norway rats
46. Inflammatory mediators of asthma: An update
47. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma
48. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast
49. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study
50. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years
51. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial
52. Montelukast added to budesonide in children with persistent asthma: A randomized, double-blind, crossover study
53. Montelukast dose selection in children ages 2 to 5 years: Comparison of population pharmacokinetics between children and adults
54. Montelukast dose selection in 6- to 14-year-olds: Comparison of single-dose pharmacokinetics in children and adults
55. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections
56. Clinical pharmacology of montelukast
57. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers
58. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene, receptor antagonist, in human plasma and bile
59. 4 receptor antagonist, in humans
60. Determination of montelukast (MK-0476) and its S-enantiomer in human plasma by stereoselective high-performance liquid chromatography with column-switching
61. Metabolism of montelukast is increased by multiple doses of phenobarbital
62. Effect of montelukast on single-dose theophylline pharmacokinetics
63. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
64. 1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers
65. Montelukast (MON) has no effect on terfenadine (T) pharmacokinetics (PK) or QTc
66. 4 receptor antagonist, montelukast (M), on ethinyl estradiol (EE) and norethindrone (NET) serum concentrations
67. Clinical efficacy of montelukast in adults and children
68. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older
69. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: A multicenter, randomized, open-label, crossover study in children with mild to moderate persistent asthma
70. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: Results of an open-label extension study evaluating long-term safety, satisfaction and adherence with therapy
71. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma
72. Chronobiology of exercise-induced bronchoconstriction in pediatric asthma: Response to montelukast
73. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged >6 years
74. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist
75. 4) receptor antagonist, in patients with chronic asthma
76. Pilot study of short-term growth in asthmatic children on montelukast
77. Montelukast associated Churg-Strauss syndrome
78. Montelukast and the Churg-Strauss syndrome
79. Pulmonary eosinophilia associated with montelukast
80. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast
81. Zafirlukast and Churg-Strauss syndrome
82. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast
83. Difficult asthma or Churg-Strauss syndrome? Steroids may be masking undiagnosed cases of Churg-Strauss syndrome
84. Formes frustes of Churg-Strauss syndrome
85. Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists
86. Churg-Strauss syndrome during pregnancy after steroid withdrawal
87. Liver disease and vasculitis in a patient taking cromolyn
88. Cardiac tamponade and peripheral eosinophilia in a patient receiving cromolyn sodium
89. Pulmonary allergic granulomatosis: A possible drug reaction in a patient receiving cromolyn sodium
90. Pulmonary infiltrates with eosinophilia in an asthmatic patient treated with disodium cromoglycate
91. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: Retrospective analysis of 58 prescription-event monitoring cohort studies
92. Leukotriene modifiers and Churg-Strauss syndrome: Adverse effect or response to corticosteroid withdrawal?
93. Leukotriene modifiers: New drugs, old and new reactions
94. Churg-Strauss syndrome and antiasthma therapy
95. Steroids and Churg-Strauss syndrome
96. Leukotriene antagonists and Churg-Strauss syndrome: The smoking gun
97. Management of asthma in children
98. Long-term effects of budesonide or nedocromil in children with asthma
99. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: A systematic review
100. Theophylline in asthma
101. Third international pediatric consensus statement on the management of childhood asthma
102. Noncompliance and treatment failure in children with asthma
103. Leukotriene modifiers in pediatric asthma management
104. Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions
105. Improvement of aspirin-intolerant asthma by Montelukast, a leukotriene antagonist. A randomized, double-blind, placebo-controlled trial
106. Effects of antileukotrienes in the treatment of asthma
107. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children